Gliadel advisory committee rescheduled

The FDA's Oncologic Drugs Advisory Committee rescheduled for Dec. 4 its review of Guilford's sNDA for Gliadel as a first-line therapy to treat malignant glioma. Gliadel is approved to treat recurrent ...